Regulation of Mdm2-directed degradation by the C terminus of p53

Molecular and Cellular Biology

Volumn 18, Issue 10, 1998, Pages 5690-5698

  Kubbutat, Michael H G ^a   Ludwig, Robert L ^a   Ashcroft, Margaret ^a   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG RECEPTOR BINDING; GENE DELETION; GENE INDUCTION; GENE TARGETING; GENETIC REGULATION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0031702817     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.10.5690     Document Type: Article

References (64)

1. Andersen, M. E., B. Woelker, M. Reed, P. Wang, and P. Tegtmeyer. 1997. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. Mol. Cell. Biol. 17:6255-6264.
2. Armstrong, J. F., M. H. Kaufman, D. J. Harrison, and A. R. Clarke. 1995. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5:931-936.
3. Ashcroft, M., and K. H. Vousden. Regulation of p53 function and stability by phosphorylation. Submitted for publication.
4. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm-2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.
5. Rates, S., and K. H. Vousden. 1996. p53 in signalling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:1-7.
6. Böttger, A., V. Böttger, A. Sparks, L. W.-L., S. F. Howard, and D. P. Lane. 1997. Design of a synthetic Mdm-2 binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:860-869.
7. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-556.
8. Caelles, C., A. Helm berg, and M. Karin. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223.
9. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16:2445-2452.
10. Chen, J. D., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
11. Crook, T., R. L. Ludwig, N. J. Marston, D. Willkomm, and K. H. Vousden. 1996. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Virology 217:285-292.
12. Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden. 1994 Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817-827.
13. Crook, T., J. A. Tidy, and K. H. Vousden. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactivation. Cell 67:547-556.
14. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.
15. Donehower, L. A. 1996. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7:269-278.
16. Fritsche, M., C. Haessler, and G. Brandner. 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318.
17. Fu, L., and S. Benchimol. 1997. Participation of the human p53 3′UTR in translational repression and activation following gamma-irradiation. EMBO J. 16:4117-4127.
18. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
19. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the C-terminal domain. Cell 90:595-606.
20. Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596-1606.
21. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
22. Haupt, Y., S. Rowan, E. Shaulian, K. H. Vousden, and M. Oren. 1995. Induction of apoptosis in HeLa cells by trans-activation deficient p53. Genes Dev. 9:2170-2183.
23. Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
24. Huibregtse, J. M., M. Sdieffner, and P. M. Howley. 1993. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol. Cell. Biol. 13: 775-784.
25. Hupp, T. R., and D. P. Lane. 1994. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp. Quant. Biol. 59:195-206.
26. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
27. Hupp, T. R., A. Sparks, and D. P. Lane. 1995. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245.
28. Jayaraman, L., and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81:1021-1029.
29. Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
30. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
31. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10: 1054-1072.
32. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
33. Kussie, P. H., S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, and N. P. Pavletich. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953.
34. Lane, D. P. 1992. p53, guardian of the genome. Nature 358:15-16.
35. Lu, X., S. A. Burbridge, S. Griffin, and H. M. Smith. 1997. Discordance between accumulated p53 protein levels and its transcriptional activity in response to U.V. radiation. Oncogene 13:413-418.
36. Maki, C. G., J. Huibregtse, and P. M. Howley. 1996. In vivo ubiquitination and proteosome-mediated degradation of p53. Cancer Res. 56:2649-2654.
37. Maltzman, W., and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694.
38. Mansur, C. P., B. Marcus, S. Dalal, and E. J. Andmphy. 1995. The domain of p53 required for binding HPV16 E6 is separable from the degradation domain. Oncogene 10:457-465.
39. Marston, N. J., T. Crook, and K. H. Vousden. 1994. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9:2707-2716.
40. Marston, N. J., J. R. Jenkins, and K. H. Vousden. 1995. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6. Oncogene 10:1709-1715.
41. Marston, N. J., R. L. Ludwig, and K. H. Vousden. 1998. Activation of p53 DNA binding activity by point mutation. Oncogene, in press.
42. Mayo, L. D., J. J. Turchi, and S. J. Berberich. 1997. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57:5013-5016.
43. McCurrach, M. E., T. M. F. Connor, M. C. Knudson, S. J. Korsmeyer, and S. W. Lowe. 1997. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 94:2345-2349.
44. Midgley, C. A., and D. P. Lane. 1997. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179-1189.
45. Mom and, J., G. P. Zambetti, D. L. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediatcd transactivation. Cell 69:1237-1245.
46. Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206.
47. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
48. Picksley, S. M., B. Vojtesek, A. Sparks, and D. P. Lane. 1994. Immunochemical analysis of the interaction of p53 with MDM2 - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9:2523-2529.
49. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723.
50. Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554-564.
51. Scheffner, M., J. M. Huibregtse, R. D. Vierstra, and P. M. Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
52. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
53. Shaw, P., J. Freeman, R. Bovey, and R. Iggo. 1996. Regulation of specific DNA binding by p53: evidence for a role of O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12:921-930.
54. Shieh, S.-Y., M. Iktda, V. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
55. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J., in press.
56. Stürzbecher, H. W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513-1523.
57. Sun, Y., J. Bian, Y. Wang, and C. Jacobs. 1997. Activation of p53 transcriptional activity by 1,10-phenanthroline. a metal chelator and redox sensitive compound. Oncogene 14:385-393.
58. Tarunina, M., and J. R. Jenkins. 1993. Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity. Oncogene 7:3165-3173.
59. Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523-526.
60. waf1/cip1. Genes Dev. 8:2817-2830.
61. Waldman, T., K. W. Kinzler, and B. Vogelstein. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
62. Wu, X. W., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53 mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
63. Yin, C., C. M. Knudson, S. J. Korsmeyer, and T. Van Dyke. 1997. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385:637-640.
64. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.